PNC-27 – 30mg Peptide

PNC-27 (30mg) — Research Compound

PNC-27 is a synthetic peptide derived from the tumor suppressor protein p53 and engineered to selectively interact with cancer cell membranes. In research settings, it is studied for its unique mechanism of targeting malignant cells through membrane disruption, making it a subject of interest in experiments involving malignant cell targeting.

Findings from early-stage clinical trials have reported:

• Selective induction of apoptosis in cancer cell lines observed in-vitro.
• Disruption of cancer cell membrane integrity reported in experimental research cohorts.
• Minimal impact on healthy cell viability noted across comparative studies.
• Observed inhibition of tumor growth markers reported in animal models.

Researchers use PNC-27 to investigate targeted anti-cancer mechanisms and the selective vulnerability of malignant cells, with a focus on understanding how peptide-based interventions may distinguish between cancerous and normal tissues.

Available Formats:
This compound is available as a vial of lyophilised powder, or can be ordered in a disposable pen, a reusable pen, or a cartridge for an existing reusable pen system.

Used solely for in vitro experiments and cannot be:

• Used in clinical trials involving humans
• Administered to humans as part of an experiment or investigation
• Supplied to another party for human investigational use

References

Anticancer peptide PNC-27 kills cancer cells by unique mechanism
This PubMed-indexed paper explains how PNC-27 binds to the p53-binding site of HDM-2 and induces transmembrane pore formation in cancer cell research models.
Source Link: Available here

The anti-cancer peptide PNC-27 induces tumour cell lysis as the intact peptide
This study investigated PNC-27 as a membrane-active peptide that binds HDM-2 and forms pores in cancer cell membranes while sparing normal cell models.
Source Link: Available here

Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and targets cancer cell membranes
This study provides structural and mechanistic context for PNC-27’s HDM-2 targeting and selective membranolysis in cancer research.
Source Link: Available here